Media stories about Versartis (NASDAQ:VSAR) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Versartis earned a media sentiment score of 0.14 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.9328573914543 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
These are some of the media stories that may have impacted Accern Sentiment’s scoring:
- Volatile Stock Characteristics – Versartis, Inc., (NASDAQ: VSAR) – Stock Watch (stocksnewstimes.com)
- Versartis, Inc. (NASDAQ: VSAR) – Early Moves to Watch – Alpha Beta Stock (alphabetastock.com)
- Versartis, Inc. (VSAR) Needs Strong Boost to Get Active Moment in Street – Stock News Stop (stockmarketstop.com)
- IMMU Up On Breast Cancer Trial Data, VTVT Awaits Major Event, No Stopping APVO (markets.businessinsider.com)
- Srinivas Akkaraju Buys 419,700 Shares of Versartis, Inc. (VSAR) Stock (americanbankingnews.com)
Shares of Versartis (NASDAQ:VSAR) remained flat at $$2.25 during midday trading on Friday. The company’s stock had a trading volume of 677,480 shares, compared to its average volume of 1,050,341. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.11. Versartis has a one year low of $1.60 and a one year high of $24.00.
VSAR has been the topic of several research analyst reports. ValuEngine cut Versartis from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Cowen restated an “outperform” rating and issued a $45.00 target price on shares of Versartis in a report on Wednesday, August 23rd. Zacks Investment Research upgraded Versartis from a “sell” rating to a “hold” rating in a report on Wednesday, August 30th. Piper Jaffray Companies restated a “buy” rating and issued a $26.00 target price on shares of Versartis in a report on Friday, September 8th. Finally, Barclays cut Versartis from an “overweight” rating to an “equal weight” rating and decreased their target price for the stock from $28.00 to $4.00 in a report on Friday, September 22nd. One analyst has rated the stock with a sell rating, nine have issued a hold rating and three have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $7.22.
In other Versartis news, Director Srinivas Akkaraju bought 419,700 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was acquired at an average price of $2.13 per share, with a total value of $893,961.00. Following the completion of the transaction, the director now directly owns 14,955 shares in the company, valued at approximately $31,854.15. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Life Sciences Maste Perceptive sold 2,130,000 shares of the firm’s stock in a transaction on Friday, September 22nd. The stock was sold at an average price of $3.29, for a total value of $7,007,700.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,132,769 shares of company stock valued at $7,014,761. 10.90% of the stock is currently owned by insiders.
Versartis Company Profile
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.